ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

SNSS Sunesis Pharmaceuticals Inc

5.32
0.00 (0.00%)
Last Updated: 01:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Sunesis Pharmaceuticals Inc NASDAQ:SNSS NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.32 4.72 4.75 0 01:00:00

Sunesis Pharmaceuticals to Present at the Rodman & Renshaw Healthcare Conference

31/10/2006 1:30pm

PR Newswire (US)


Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart


From Oct 2019 to Oct 2024

Click Here for more Sunesis Pharmaceuticals Charts.
SOUTH SAN FRANCISCO, Calif., Oct. 31 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) today announced that James W. Young, Ph.D., Executive Chairman, will present a corporate update at the Rodman & Renshaw 8th Annual Healthcare Conference on Monday, November 6, 2006 at 12:25 p.m. Eastern Time at the Palace Hotel in New York, NY. Interested parties may access a webcast of the presentation by visiting the Sunesis website at http://ir.sunesis.com/ . A replay of the webcast will be archived on the "Calendar of Events" page in the Investors and Media section of the Sunesis website for two weeks until November 20, 2006. About Sunesis Pharmaceuticals Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. Sunesis is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. For additional information on Sunesis Pharmaceuticals, please visit http://www.sunesis.com/ . Forward-Looking Statements This press release may contain forward-looking statements that involve substantial risks and uncertainties. Sunesis may not actually achieve the plans, intentions or expectations contained in such forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations contained in such forward-looking statements. Sunesis does not assume any obligation to update any such forward-looking statements. DATASOURCE: Sunesis Pharmaceuticals, Inc. CONTACT: investors, Eric Bjerkholt, CFO of Sunesis Pharmaceuticals, Inc., +1-650-266-3717, or media, Karen L. Bergman or Michelle Corral of BCC Partners, +1-650-575-1509, or +1-415-794-8662, for Sunesis Pharmaceuticals, Inc. Web site: http://www.sunesis.com/

Copyright

1 Year Sunesis Pharmaceuticals Chart

1 Year Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

1 Month Sunesis Pharmaceuticals Chart

Your Recent History

Delayed Upgrade Clock